###begin article-title 0
###xml 24 28 24 28 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes
###end article-title 0
###begin p 1
###xml 130 161 130 161 <email xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rotraud.wieser@meduniwien.ac.at</email>
 Correspondence: Department of Medical Genetics, Medical University of Vienna, Waehringerstr. 10, A-1090 Vienna, Austria. e-mail: rotraud.wieser@meduniwien.ac.at
###end p 1
###begin p 2
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 13 17 13 17 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 316 320 316 320 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 554 558 554 558 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 563 572 563 572 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 718 719 718 719 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 721 722 721 722 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 821 826 821 826 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1-</italic>
###xml 830 839 830 839 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 1125 1129 1125 1129 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 615 620 <span type="species:ncbi:9606">human</span>
The oncogene EVI1 has been implicated in the etiology of AML and MDS. Although AML cells are characterized by accelerated proliferation and differentiation arrest, MDS cells hyperproliferate when immature but fail to differentiate later and die instead. In agreement with its roles in AML and in immature MDS cells, EVI1 was found to stimulate cell proliferation and inhibit differentiation in several experimental systems. In contrast, the variant protein MDS1/EVI1 caused the opposite effect in some of these assays. In the present study, we expressed EVI1 and MDS1/EVI1 in a tetracycline-regulable manner in the human myeloid cell line U937. Induction of either of these proteins caused cells to accumulate in the G0/G1-phase of the cell cycle and moderately increased the rate of spontaneous apoptosis. However, when EVI1- or MDS1/EVI1-expressing cells were induced to differentiate, they massively succumbed to apoptosis, as reflected by the accumulation of phosphatidylserine in the outer leaflet of the plasma membrane and increased rates of DNA fragmentation. In summary, these data show that inducible expression of EVI1 in U937 cells causes phenotypes that may be relevant for its role in MDS and provides a basis for further investigation of its contribution to this fatal disease.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 149 150 149 150 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 492 493 492 493 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 495 496 495 496 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 839 840 839 840 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 975 976 975 976 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 978 979 978 979 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">3</xref>
###xml 1245 1246 1245 1246 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 1266 1271 1266 1271 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N-RAS</italic>
###xml 1283 1286 1283 1286 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 1366 1367 1366 1367 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 1560 1563 1560 1563 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 1568 1572 1568 1572 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1629 1630 1629 1630 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 1632 1633 1632 1633 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 1123 1131 <span type="species:ncbi:9606">patients</span>
###xml 1396 1404 <span type="species:ncbi:9606">patients</span>
MDS are a group of clonal malignant hematopoietic diseases with an annual incidence of two to 12 per 100,000 and an almost invariably fatal outcome [1]. Approximately one-third of the patients die, as the disease progresses into therapy-resistant sAML, and the remaining two-thirds succumb to the complications of peripheral blood pancytopenia. Reduced blood cell counts with concomitant hyper- or normoplasia and dysplasia of bone marrow are the principal biological characteristics of MDS [1, 2]. These apparently contradictory features are attributed to the increased proliferation of immature cells, accompanied by high rates of apoptosis in maturing cells. The latter phenomenon has been termed differentiation failure and contributes markedly to, but probably does not fully account for, the peripheral blood hypocellularity in MDS [1]. The molecular and genetic basis of MDS is poorly understood, and no MDS-specific genetic alterations have been identified thus far [2, 3]. Point mutations in the gene for the hematopoietic transcription factor AML1, which are rare but recurrent in AML, have been found in >20% of patients with advanced MDS and constitute the most frequent, currently known molecular alteration in this disease entity [4]. Mutations in the N-RAS, FLT3, and MLL genes have also been observed in MDS but significantly less often than in AML [5]. Approximately one-half of patients with MDS bears cytogenetic abnormalities such as deletions in or losses of chromosomes 5, 7, 17, or 20, trisomy 8, or structural aberrations affecting the MLL and EVI1 genes in chromosome bands 11q23 and 3q26, respectively [1, 2].
###end p 5
###begin p 6
###xml 93 97 93 97 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 157 158 157 158 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 160 161 160 161 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 163 164 163 164 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 166 167 166 167 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 183 187 183 187 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 288 289 288 289 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 289 290 289 290 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 290 291 290 291 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 291 293 291 293 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 293 295 293 295 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 347 349 347 349 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">12</xref>
###xml 351 353 351 353 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 455 456 455 456 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 458 460 458 460 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 460 462 460 462 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">15</xref>
###xml 462 464 462 464 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">16</xref>
###xml 464 466 464 466 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B17" ref-type="bibr">17</xref>
###xml 578 580 578 580 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">12</xref>
###xml 582 584 582 584 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">15</xref>
###xml 586 588 586 588 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 773 775 773 775 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 775 777 775 777 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 777 779 777 779 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 779 781 779 781 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
Rearrangements of chromosome band 3q26, the majority of which leads to overexpression of the EVI1 gene, are found in AML, chronic myeloid leukemia, and MDS [1, 2, 6, 7]. In addition, EVI1 is expressed aberrantly in some cases of these disease entities as a result of yet-unknown reasons [7891011]. It codes for a zinc finger transcription factor [12, 13] and through alternative promoter use and alternative splicing, gives rise to several mRNA variants [7, 14151617]. These are translated into two major protein forms: the 145-kD EVI1 protein and the 170-kD MDS1/EVI1 protein [12, 15, 18]. MDS1/EVI1, which differs from EVI1 by the presence of an N-terminal PR domain, exhibited biological activity contrary to or different from that of EVI1 in some experimental systems [18192021].
###end p 6
###begin p 7
###xml 15 19 15 19 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 135 137 135 137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 139 141 139 141 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 143 145 143 145 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">22</xref>
###xml 231 235 231 235 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 345 347 345 347 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 349 351 349 351 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 353 355 353 355 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 355 357 355 357 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">24</xref>
###xml 357 359 357 359 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 371 375 371 375 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 464 465 464 465 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 465 466 465 466 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 466 468 466 468 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 468 470 468 470 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 550 554 550 554 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 635 637 635 637 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 639 641 639 641 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 740 744 740 744 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 777 782 777 782 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 794 796 794 796 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 815 819 815 819 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">AML1</italic>
###xml 826 828 826 828 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B26" ref-type="bibr">26</xref>
###xml 872 876 872 876 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1112 1116 1112 1116 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
Research about EVI1 has focused largely on its role in AML, as its overexpression in this disease is associated with a poor prognosis [10, 11, 22]. In agreement with a contribution to the pathogenesis of AML, the overexpression of EVI1 promoted cellular proliferation and inhibited differentiation and apoptosis in certain experimental systems [13, 19, 232425]. However, EVI1 levels appear to be increased even more frequently in MDS and sAML than in de novo AML [891011]. Furthermore, mice transplanted with bone marrow cells ectopically expressing EVI1 developed a fatal disorder resembling human MDS but without progression to AML [23, 25]. The latter disease emerged only when mice were transplanted with bone marrow cells coexpressing EVI1 with the leukemogenic oncogenes HOXA9 and MEIS1 [25] or with a mutant AML1 gene [26]. These observations suggest that in vivo, EVI1 promoted the proliferation of immature cells but exerted antiproliferative and/or proapoptotic effects that counteracted further cellular expansion in more differentiated cells. Full-blown leukemia developed only when this property of EVI1 was overcome by additional genetic events.
###end p 7
###begin p 8
###xml 60 64 60 64 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 68 77 68 77 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 85 90 <span type="species:ncbi:9606">human</span>
In the present study, we found that inducible expression of EVI1 or MDS1/EVI1 in the human myelomonocytic cell line U937T led to cell-cycle arrest and massive apoptosis upon exposure to differentiation stimuli, thereby recapitulating salient aspects of the biology of MDS in vitro.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Plasmids, cell culture, and transfections
###end title 10
###begin p 11
###xml 683 685 683 685 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">27</xref>
###xml 65 70 <span type="species:ncbi:9606">human</span>
The plasmids EVI1-HA/pUHD10S and MDS1/EVI1-HA/pUHD10S harbor the human EVI1 and MDS1/EVI1 cDNAs, respectively, both with HA epitope tags at their 3'-ends in the pUHD10S vector backbone. The epitope tags did not affect the activities of EVI1 and MDS1/EVI1 in reporter gene assays. In addition, preliminary data suggested that transient transfection of a plasmid harboring an untagged EVI1 cDNA into U937 cells led to a growth phenotype similar to that observed upon induction of EVI-HA in stably transfected U937 cells (T. A. Konrad, unpublished results). pUHD10S contains seven copies of the tetracycline operator, facilitating tetracycline-regulable expression of its cDNA inserts [27].
###end p 11
###begin p 12
###xml 185 187 185 187 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 258 259 252 253 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 39 44 <span type="species:ncbi:9606">human</span>
U937T cells had been derived from U937 human histiocytic lymphoma cells by stable transfection with a construct driving tetracycline-regulable expression of the tetVP16 fusion protein [28]. They were cultured in a humidified incubator at 37degreesC and 5% CO2 in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Invitrogen), 0.5 mug/ml puromycin (Sigma Chemical Co., St. Louis, MO, USA), and 1 mug/ml tetracycline (Serva Electrophoresis, Germany). To obtain U937T_EVI1-HA and U937T_MDS1/EVI1-HA cells, the plasmids EVI1-HA/pUHD10S and MDS1/EVI1-HA/pUHD10S were electroporated (0.17 kV, 950 muF) into U937T cells. Transfectants were selected, cloned, and propagated in RPMI-1640 medium supplemented with 10% FBS, 0.5 mug/ml puromycin, 1 mug/ml tetracycline, and 500 mug/ml hygromycin (PAA, Austria). To induce the expression of EVI1-HA or MDS1/EVI1-HA, exponentially growing cells were washed three times with PBS and resuspended in growth media without tetracycline. Control cultures were washed in the same manner but resuspended in media with tetracycline. To induce differentiation, TPA, at a final concentration of 50 ng/ml, was added to cells that had been transferred to media with or without tetracycline and adjusted to a density of 60 cells/mul on the previous day (Day 0 of the experiment). Control cultures were treated with an equivalent amount of solvent (ethanol).
###end p 12
###begin p 13
###xml 8 10 8 10 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">29</xref>
###xml 27 29 27 29 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B30" ref-type="bibr">30</xref>
###xml 70 71 64 65 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
HNT-34 [29] and MPD cells [30] were maintained at 37degreesC and 5% CO2 in RPMI-1640 medium supplemented with 10% FBS.
###end p 13
###begin title 14
Immunoblot and immunofluorescence analyses
###end title 14
###begin p 15
###xml 638 643 <span type="species:ncbi:10090">mouse</span>
###xml 704 710 <span type="species:ncbi:9986">rabbit</span>
###xml 792 797 <span type="species:ncbi:10090">mouse</span>
###xml 936 940 <span type="species:ncbi:9925">goat</span>
###xml 946 951 <span type="species:ncbi:10090">mouse</span>
###xml 956 960 <span type="species:ncbi:9925">goat</span>
###xml 966 972 <span type="species:ncbi:9986">rabbit</span>
U937T cells and their derivatives were transferred to media containing the specified concentrations of tetracycline. After the indicated periods of time, protein extracts were prepared by subjecting cells to repeated freeze-thawing in a buffer consisting of 20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 0.5 mM PMSF, and protease inhibitor cocktail (Roche, Nutley, NJ, USA). Polyacrylamide gel electrophoresis, tank-blotting onto Bio Trace NT nitrocellulose membranes (Pall Corp., East Hills, NY, USA), and antibody hybridizations were performed using standard procedures. Primary antibodies directed against the HA-tag (mouse anti-HA.11 clone 16B12, Covance, Princeton, NJ, USA), EVI1 (rabbit anti-EVI1 C50E12, Cell Signaling Technology, Beverly, MA, USA), or beta-tubulin (mouse anti-beta-tubulin clone TUB 2.1, Sigma Chemical Co.) were used at dilutions of 1:10,000, 1:1000, and 1:2500, respectively. HRP-conjugated goat anti-mouse and goat anti-rabbit secondary antibodies were used at dilutions of 1:50,000-1:100,000 and detected by the Super Signal West Femto kit (Pierce, Rockford, IL, USA).
###end p 15
###begin p 16
###xml 465 466 465 466 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 252 256 <span type="species:ncbi:9925">goat</span>
###xml 380 384 <span type="species:ncbi:9925">goat</span>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
###xml 443 447 <span type="species:ncbi:9925">goat</span>
###xml 453 458 <span type="species:ncbi:10090">mouse</span>
For immunofluorescence analysis, U937T cells and their derivatives were transferred to media with or without tetracycline and spun onto coverslips 48 h later. Cells were fixed with 100% methanol, permeabilized with 1% Triton X-100, and blocked with 5% goat serum (PAA). Cells were incubated with the HA antibody at a dilution of 1:200, followed by a fluorescein (FITC)-conjugated goat anti-mouse secondary antibody [FITC-conjugated AffiniPure goat anti-mouse IgG (H+L), Jackson ImmunoResearch, West Grove, PA, USA; 1:200]. Counterstaining of DNA with DAPI and mounting of coverslips were performed in one step using Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Images were obtained with an Axiovert microscope (Zeiss, Thornwood, NY, USA).
###end p 16
###begin title 17
Analyses of cellular growth and cell-cycle distribution
###end title 17
###begin p 18
To monitor cellular proliferation, exponentially growing U937T cells and their derivatives were transferred to media containing the indicated concentrations of tetracycline. During this process or 2 days later, all cultures were adjusted to the same cell density. On the indicated days after density adjustment, Trypan blue-excluding viable cells were counted in a hematocytometer.
###end p 18
###begin p 19
For cell-cycle analyses, cells were transferred to media with or without tetracycline and adjusted to the same density. After 4 days, they were washed with PBS and incubated for 5 min in ice-cold 0.5 M citrate/0.5% Tween-20. Cell membranes were disrupted mechanically before the nuclei were pelleted and resuspended in PBS containing 100 mug/ml RNase A and 50 mug/ml propidium iodide. The nuclear DNA content was analyzed on a FACSCalibur (Becton Dickinson, San Diego, CA, USA) using CellQuest Pro and ModFit software for data acquisition and analysis, respectively.
###end p 19
###begin title 20
Differentiation and apoptosis assays
###end title 20
###begin p 21
Spontaneous apoptosis was determined 5 days after exponentially growing cells had been transferred to media with or without tetracycline and adjusted to a density of 50 cells/mul. Accumulation of outer membrane leaflet phosphatidylserine and the loss of membrane integrity were assessed using the Annexin V-FITC/7-AAD kit from Beckman Coulter (Fullerton, CA, USA), according to the manufacturer's instructions. Flow cytometric analyses were performed on a FACSCalibur using CellQuest Pro software. Annexin V-negative 7-AAD-negative cells were considered viable; Annexin V-positive 7-AAD-negative cells were deemed early-apoptotic; and double-positive cells were considered late-apoptotic/necrotic.
###end p 21
###begin p 22
###xml 30 34 30 34 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 39 48 39 48 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
To investigate the effects of EVI1 and MDS1/EVI1 on cellular differentiation, cells were transferred to media with or without tetracycline and adjusted to a density of 60 cells/mul. On the following day (Day 1 of the experiment), TPA at a final concentration of 50 ng/ml was added to one-half of each culture and an equivalent amount of solvent (ethanol) to the other half. Cellular differentiation was monitored on Days 4 and 6 of the experiment by staining for the monocyte/macrophage-specific cell-surface marker CD11b. Cells were incubated in a 1:48 dilution of a PE-conjugated CD11b antibody (Becton Dickinson) in PBS for 15-30 min at room temperature in the dark. Flow cytometric analyses were performed on a FACSCalibur. The percentage of CD11b-positive cells was used as a measure of differentiation. A second aliquot of each culture was subjected to Annexin V-FITC/7-AAD staining as described above.
###end p 22
###begin p 23
For DNA fragmentation assays, cells were cultured in the presence or absence of tetracycline and TPA as described above. On Day 5 of the experiment, cells were subjected to TUNEL assays using the APO-DIRECTtrade mark kit (Becton Dickinson) according to the manufacturer's instructions. Flow cytometric analyses were performed on a FACSAria (Becton Dickinson) using FACSDivatrade mark software.
###end p 23
###begin title 24
Statistical analyses
###end title 24
###begin p 25
###xml 57 58 57 58 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 231 232 229 230 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analyses were performed using the two-tailed t-test and the software package R 2.6.0. (http://www.r-project.org/). Data derived from several independent experiments are presented as mean +/- standard error of the mean. P values <0.05 were considered significant.
###end p 25
###begin title 26
RESULTS
###end title 26
###begin title 27
###xml 17 22 <span type="species:ncbi:9606">human</span>
Establishment of human myeloid cell lines expressing EVI1 or MDS1/EVI1 in an inducible manner
###end title 27
###begin p 28
###xml 81 85 81 85 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 90 99 90 99 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 249 253 249 253 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 361 365 361 365 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 367 369 367 369 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 481 483 481 483 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 851 858 851 858 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1A</bold>
###xml 851 858 851 858 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig"><bold>Fig. 1A</bold></xref>
###xml 1089 1098 1089 1098 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1B)</xref>
###xml 1168 1177 1168 1177 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1C)</xref>
###xml 1531 1533 1531 1533 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">29</xref>
###xml 1535 1537 1535 1537 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B30" ref-type="bibr">30</xref>
###xml 1539 1548 1539 1548 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1D)</xref>
###xml 140 145 <span type="species:ncbi:9606">human</span>
###xml 536 541 <span type="species:ncbi:9606">human</span>
###xml 1490 1495 <span type="species:ncbi:9606">human</span>
U937 histiocytic lymphoma cells were chosen as a model to study the functions of EVI1 and MDS1/EVI1 in myeloid malignancies, as they are of human origin, can be stimulated to differentiate along the myelomonocytic lineage, do not express endogenous EVI1 (T. A. Konrad, unpublished observations), and have been reported to be responsive to exogenously expressed EVI1 [31]. The U937-derivative cell line U937T expresses the tetVP16 fusion protein in a tetracycline-regulated manner [28]. It was transfected with constructs containing the human EVI1 and MDS1/EVI1 cDNAs with HA epitope tags at their 3'-ends under the control of a tetVP16-responsive promoter. After hygromycin selection, U937T_EVI1-HA clones E10 and E14 and U937T_MDS1/EVI1-HA clones M2 and M27, which upon removal of tetracycline strongly induced EVI1-HA or MDS1/EVI1-HA, respectively (Fig. 1A), were selected for further investigation. Time-course experiments showed that the exogenously expressed proteins were highly abundant as early as 12 h after tetracycline withdrawal and continued to be elevated for at least 120 h (Fig. 1B). Immunofluorescence analysis confirmed their location in the nucleus (Fig. 1C). During these investigations, a purchasable antibody capable of detecting endogenous EVI1 became available and was used to show that exogenous protein levels in U937T_EVI1-HA and U937T_MDS1/EVI1-HA cells 48 h after removal of tetracycline were comparable with endogenous EVI1 and MDS1/EVI1 protein levels in the human myeloid cell lines HNT-34 and MPD [29, 30] (Fig. 1D).
###end p 28
###begin title 29
Induction of EVI1 or MDS1/EVI1 reduces the proliferation of U937T cells
###end title 29
###begin p 30
###xml 43 47 43 47 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 52 61 52 61 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 362 366 362 366 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 370 379 370 379 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 514 521 514 521 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2A</bold>
###xml 514 521 514 521 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig"><bold>Fig. 2A</bold></xref>
To investigate the effects of experimental EVI1 and MDS1/EVI1 expression on cell proliferation, U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and U937T cells were transferred to media with or without tetracycline. Two days later, they were adjusted to the same starting cell density. Viable cells were then counted daily over a period of 6 days. Unexpectedly, induction of EVI1 or MDS1/EVI1 strongly inhibited cell proliferation, while control U937T cells grew at comparable rates in the presence or absence of tetracycline (Fig. 2A). Similar results were obtained when cells were cultured in media containing 1% rather than 10% FBS (data not shown).
###end p 30
###begin p 31
###xml 361 370 361 370 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2B)</xref>
###xml 550 559 550 559 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2C)</xref>
To determine whether EVI1 inhibited cellular growth in a dose-dependent manner, E14 cells were transferred to media containing 1000, 5, 3, 2, 0.5, or 0 ng/ml tetracycline. Immunoblot analysis was performed on protein extracts derived 3 days after transfer to these media and showed that EVI1 protein levels increased with decreasing tetracycline concentrations (Fig. 2B). Accordingly, cell growth was maximal or near-maximal in the presence of 1000, 5, and 3 ng/ml tetracycline, intermediate at 2, and strongly reduced at 0.5 or 0 ng/ml tetracycline (Fig. 2C).
###end p 31
###begin p 32
###xml 56 60 56 60 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 64 73 64 73 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 524 528 512 516 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 660 661 648 649 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 663 664 651 652 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 677 686 665 674 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3, A</bold>
###xml 691 692 679 680 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 677 692 665 680 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig"><bold>Fig. 3, A</bold> and <bold>B</bold></xref>
###xml 774 791 762 779 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3, A and B)</xref>
###xml 817 819 805 807 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 929 946 917 934 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3, A and B)</xref>
###xml 1067 1071 1055 1059 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1075 1084 1063 1072 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
The reduced proliferation after exogenous expression of EVI1 or MDS1/EVI1 could be a result of slowed cell-cycle progression, increased apoptosis, or a combination of both. To address the first possibility, the nuclei of cells that had been maintained in the presence or absence of tetracycline for 4 days were stained with propidium iodide and analyzed by flow cytometry. In the presence of tetracycline, approximately40% of the cells were in S-phase, consistent with the rapid growth observed under these conditions. When EVI1 was induced through removal of tetracycline, the percentage of cells in S-phase dropped to 4%, with a concomitant increase of the G0/G1 population (Fig. 3, A and B). A similar but slightly milder effect was observed for U937T_MDS1/EVI1-HA cells (Fig. 3, A and B). As reported previously [28], the percentage of cells in S-phase was also somewhat reduced upon removal of tetracycline from U937T cells (Fig. 3, A and B), but this nonspecific effect was significantly milder than the specific effect observed as a result of the induction of EVI1 or MDS1/EVI1.
###end p 32
###begin p 33
###xml 35 39 35 39 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 43 52 43 52 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 508 514 508 514 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4</bold>
###xml 508 514 508 514 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig"><bold>Fig. 4</bold></xref>
To determine whether expression of EVI1 or MDS1/EVI1 caused cells to undergo apoptosis, U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and U937T cells were maintained in the presence or absence of tetracycline for 5 days, stained with FITC-conjugated Annexin V and 7-AAD, and analyzed by flow cytometry. Tetracycline removal was found to cause a small but significant proportion of U937T_EVI1-HA cells to undergo apoptosis. This effect was more pronounced in U937T_MDS1/EVI1-HA cells but absent in parental U937T cells (Fig. 4).
###end p 33
###begin p 34
###xml 12 16 12 16 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 21 30 21 30 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
In summary, EVI1 and MDS1/EVI1 inhibited U937T cell proliferation, primarily by causing cell-cycle arrest and to a minor extent by increasing the rate of spontaneous apoptosis.
###end p 34
###begin title 35
U937T cells expressing EVI1 or MDS1/EVI1 undergo massive apoptosis when stimulated to differentiate
###end title 35
###begin p 36
###xml 30 34 30 34 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 39 48 39 48 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 600 606 600 606 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5</bold>
###xml 600 606 600 606 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig"><bold>Fig. 5</bold></xref>
###xml 731 739 731 739 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 879 887 879 887 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 1111 1119 1111 1119 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 1581 1589 1581 1589 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 1916 1924 1916 1924 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 1973 1981 1973 1981 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5)</xref>
###xml 2053 2057 2053 2057 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 2061 2070 2061 2070 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
To investigate the effects of EVI1 and MDS1/EVI1 on cellular differentiation, U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and control U937T cells were transferred to media with or without tetracycline, and the differentiation-inducing agent TPA was added to one-half of each culture on the following day (Day 1 of the experiment). On Days 4 and 6, cellular differentiation was monitored by flow cytometric analysis for the monocyte/macrophage-specific cell-surface marker CD11b. As expected, TPA caused a time-dependent increase in the percentage of CD11b-positive cells in all three investigated cell types (Fig. 5). Similarly, removal of tetracycline led to enhanced CD11b expression in U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and U937T cells (Fig. 5). This effect was strongest in U937T_EVI1-HA cells and least pronounced in U937T cells. In the latter cell line, it also declined over time (Fig. 5), probably as a result of overgrowth of differentiated cells by cycling cells. Addition of TPA after tetracycline withdrawal caused an only moderately stronger effect on cell-surface CD11b levels than either treatment alone (Fig. 5). However, a markedly increased rate of cell death was noted in U937T_EVI1-HA and U937T_MDS1/EVI1-HA cells under these conditions. To investigate this phenomenon further, aliquots of the cultures used for CD11b staining were labeled with Annexin V-FITC and 7-AAD and subjected to flow cytometry. Removal of tetracycline led to a moderate increase in apoptosis in U937T_EVI1-HA and U937T_MDS1/EVI1-HA cells but not parental U937T cells on Day 6 of the experiment (Fig. 5). Addition of TPA to tetracycline-containing cultures caused the death of a small proportion of cells of all three types. Notably, a marked and synergistic increase in the numbers of dying and dead cells was observed when U937T_EVI1-HA and U937T_MDS1/EVI1-HA cells were exposed to TPA after transfer to tetracycline-free media (Fig. 5). This effect was absent in parental U937T cells (Fig. 5), demonstrating that it was a specific consequence of the expression of EVI1 or MDS1/EVI1.
###end p 36
###begin p 37
###xml 395 404 395 404 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 6, A</bold>
###xml 409 410 409 410 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 395 410 395 410 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig"><bold>Fig. 6, A</bold> and <bold>B</bold></xref>
###xml 499 516 499 516 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">(Fig. 6, A and B)</xref>
###xml 569 573 569 573 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 577 586 577 586 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
To corroborate these results, U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and U937T cells were cultured as described above and subjected to TUNEL assays on Day 5 of the experiment. Again, a limited proportion of U937T_EVI1-HA cells underwent programmed death upon exposure to TPA or removal of tetracycline, and the combination of these treatments caused a more-than-additive proportion of cells to die (Fig. 6, A and B). Similar effects were seen in U937T_MDS1/EVI1-HA cells but not in parental U937T cells (Fig. 6, A and B). In summary, these data show that the expression of EVI1 or MDS1/EVI1 causes massive apoptosis in cells exposed to a differentiation stimulus.
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 22 26 22 26 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 94 95 94 95 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 95 96 95 96 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 96 97 96 97 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 97 98 97 98 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 98 100 98 100 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 100 102 100 102 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 182 186 182 186 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Evi1</italic>
###xml 247 249 247 249 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 251 253 251 253 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 253 255 253 255 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">24</xref>
###xml 255 257 255 257 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 259 261 259 261 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B32" ref-type="bibr">32</xref>
###xml 263 265 263 265 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B33" ref-type="bibr">33</xref>
###xml 419 421 419 421 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 423 425 423 425 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B34" ref-type="bibr">34</xref>
###xml 428 432 428 432 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 512 514 512 514 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">24</xref>
###xml 516 518 516 518 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 520 522 520 522 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B35" ref-type="bibr">35</xref>
###xml 612 614 612 614 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 616 618 616 618 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B36" ref-type="bibr">36</xref>
###xml 642 646 642 646 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 749 753 749 753 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 939 943 939 943 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1046 1050 1046 1050 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Evi1</italic>
###xml 1138 1140 1138 1140 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 1142 1144 1142 1144 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 1305 1307 1305 1307 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 1309 1311 1309 1311 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 1449 1453 1449 1453 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1549 1551 1549 1551 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">37</xref>
###xml 1554 1558 1554 1558 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1677 1679 1677 1679 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 1681 1683 1681 1683 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B36" ref-type="bibr">36</xref>
###xml 1685 1687 1685 1687 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B38" ref-type="bibr">38</xref>
###xml 1689 1691 1689 1691 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B39" ref-type="bibr">39</xref>
###xml 1712 1716 1712 1716 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Evi1</italic>
###xml 1854 1856 1854 1856 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 1858 1860 1858 1860 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B38" ref-type="bibr">38</xref>
###xml 1862 1864 1862 1864 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B40" ref-type="bibr">40</xref>
###xml 2001 2005 2001 2005 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 2099 2100 2099 2100 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 2102 2103 2102 2103 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 371 377 <span type="species:ncbi:10090">murine</span>
###xml 1083 1088 <span type="species:ncbi:10090">mouse</span>
###xml 1203 1207 <span type="species:ncbi:10090">mice</span>
###xml 1604 1609 <span type="species:ncbi:9606">human</span>
###xml 1728 1734 <span type="species:ncbi:10090">murine</span>
###xml 2013 2018 <span type="species:ncbi:9606">human</span>
Overexpression of the EVI1 gene is presumed to contribute to the pathogenesis of AML and MDS [67891011]. In agreement with its role in the former disease, experimental expression of Evi1 enhanced the proliferation of immature hematopoietic cells [19, 232425, 32, 33], and targeted disruption of its gene locus impaired proliferation and enhanced spontaneous apoptosis of murine hematopoietic stem and progenitor cells [13, 34]. EVI1 inhibited programmed cell death in response to a variety of apoptotic stimuli [24, 31, 35], and its ectopic expression interfered with erythroid and granulocytic differentiation [23, 36]. Of these phenotypes, EVI1-mediated augmentation of proliferation and survival is not only likely to be relevant for the role of EVI1 in AML but may also contribute to the bone marrow hypercellularity observed frequently in MDS. However, more mature MDS cells are impaired in their ability to grow and survive. Indeed, EVI1 also evoked phenotypes that may be related to this aspect of the disease. Thus, ectopic expression of Evi1 caused an MDS-like disease in a mouse bone marrow transduction/transplantation system [23, 25]. Compared with controls, bone marrow cells from diseased mice yielded reduced numbers of colonies in soft agar containing differentiation-promoting cytokines [23, 25], most likely reflecting impaired growth and/or enhanced rates of cell death. In ovarian epithelial cells, only short-term expression of EVI1 increased proliferation, whereas long-term expression strongly reduced growth and/or survival [37]. EVI1 overexpression also delayed proliferation of human myeloid UT-7/GM cells and of erythroid cells from various sources [23, 36, 38, 39]. Furthermore, when Evi1-transduced murine 32Dcl3 or 32DEpo cells were induced to differentiate, they lost their viability in a manner not characterized further [20, 38, 40], possibly reflecting the phenotype of differentiation failure. In the present investigation, it was found that inducible expression of EVI1 in the human myeloid cell line U937T caused cells to cease proliferation, accumulate in the G0/G1-phase of the cell cycle, increase cell-surface CD11b expression, undergo a mild degree of spontaneous apoptosis, and massively succumb to programmed cell death when induced to differentiate.
###end p 39
###begin p 40
###xml 68 69 68 69 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 71 72 71 72 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 159 161 159 161 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 409 413 409 413 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 610 612 610 612 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B41" ref-type="bibr">41</xref>
###xml 792 796 792 796 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 980 981 980 981 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 983 984 983 984 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1267 1268 1267 1268 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1270 1271 1270 1271 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1553 1555 1553 1555 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B42" ref-type="bibr">42</xref>
###xml 1557 1559 1557 1559 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B43" ref-type="bibr">43</xref>
Notably, tetracycline withdrawal caused a shift from the S- to the G0/G1-phase of the cell cycle, not only in U937T_EVI1-HA cells but, as reported previously [28], in parental U937T cells as well. However, the alterations in cell-cycle distribution were significantly more pronounced in U937T_EVI1-HA cells than in the parental line. Therefore, they appear to constitute a genuine and specific consequence of EVI1 expression. Similarly, removal of tetracycline led to increased cell-surface CD11b expression in U937T_EVI1-HA and in U937T cells. Again, this effect has been reported previously for U937T cells [41] but was less pronounced than in U937T_EVI1-HA cells in our experiments. Although we cannot rule out the possibility of differentiation being induced as a specific consequence of EVI1 expression in U937T cells, we believe it is more likely a secondary effect of cell-cycle arrest. This assumption is supported by the following observations: First, the extent of the G0/G1 arrest correlated with that of CD11b induction in the cell lines used in this study. Second, a large proportion of U937T cells remained in a cycling state and outgrew the CD11b-positive cells over time, whereas in the U937T_EVI1-HA clones, of which virtually all cells arrested in G0/G1, cell-surface CD11b expression increased with time. Third, it has been shown previously that cell-cycle arrest caused by experimental expression of the cyclin-dependent kinase inhibitors p21 and p27 or by glutamine depletion was sufficient to induce differentiation of U937 cells [42, 43], suggesting that cell-cycle arrest per se is sufficient to promote differentiation in this cell line.
###end p 40
###begin p 41
###xml 56 60 56 60 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 242 246 242 246 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 407 411 407 411 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 480 489 480 489 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1A)</xref>
###xml 523 527 523 527 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 699 703 699 703 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 825 829 825 829 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1018 1022 1018 1022 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1239 1243 1239 1243 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
The most striking phenotype observed after induction of EVI1, namely, the occurrence of massive apoptosis after exposure to a differentiation signal, was entirely absent in parental cells, showing that it was a genuine and specific effect of EVI1. Interestingly, TPA caused a higher rate of cell death in U937T_EVI1-HA than in U937T cells even in the presence of tetracycline. This may be a result of basal EVI1 expression in U937T_EVI1-HA cells in the presence of the antibiotic (Fig. 1A) and suggests that the ability of EVI1 to cause apoptosis in cells exposed to differentiation signals is dose-dependent. For the following reasons, we believe it unlikely that the massive apoptosis observed in EVI1-expressing, TPA-treated cells was merely a consequence of excessive differentiation signals: i) the rate of apoptosis in EVI1-expressing, TPA-treated cells greatly exceeded that observed under any other conditions, including some that led to comparable degrees of CD11b positivity, and ii) the combined effects of EVI1 induction and TPA treatment on CD11b expression were only moderately greater than their individual effects, but their combined effects on apoptosis were synergistic. Therefore, our results suggest that expression of EVI1 in U937 cells causes differentiation failure, which is a key feature of MDS.
###end p 41
###begin p 42
###xml 56 58 56 58 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 92 96 92 96 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 244 248 240 244 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 337 341 333 337 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 594 599 590 595 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 690 692 686 688 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B44" ref-type="bibr">44</xref>
Our data appear to contradict those of Kurokawa et al. [31], who reported that constitutive EVI1 overexpression inhibited TNF-alpha-induced apoptosis in U937 cells. A possible explanation for this discrepancy is that constitutive expression of EVI1 may select for transfectants with genetic or epigenetic alterations that cooperate with EVI1 to promote cellular growth and survival. Alternatively, U937 cells maintained in different laboratories, or U937 and U937T cells, may exhibit certain genetic and/or gene-expression differences a priori. For example, our batch of U937 cells transcribed HOXA9, a gene highly expressed in, and important for the function of, hematopoietic stem cells [44], while U937T cells, for unknown reasons, did not (T. A. Konrad, unpublished results).
###end p 42
###begin p 43
###xml 39 43 39 43 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 48 57 48 57 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 457 459 457 459 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B45" ref-type="bibr">45</xref>
###xml 472 476 472 476 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Evi1</italic>
###xml 481 490 481 490 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mds1/Evi1</italic>
###xml 562 564 562 564 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 564 566 564 566 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 566 568 566 568 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 570 572 570 572 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">37</xref>
###xml 608 612 608 612 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Evi1</italic>
###xml 648 657 648 657 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mds1/Evi1</italic>
###xml 672 674 672 674 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 674 676 674 676 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 676 678 676 678 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
###xml 781 783 781 783 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
###xml 785 787 785 787 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">37</xref>
###xml 789 791 789 791 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B46" ref-type="bibr">46</xref>
###xml 793 795 793 795 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B47" ref-type="bibr">47</xref>
###xml 820 824 820 824 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 829 838 829 838 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 1037 1041 1037 1041 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1046 1055 1046 1055 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
###xml 1109 1111 1109 1111 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B37" ref-type="bibr">37</xref>
###xml 1125 1127 1125 1127 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 1229 1233 1229 1233 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1238 1247 1238 1247 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MDS1/EVI1</italic>
A further, unexpected finding was that EVI1 and MDS1/EVI1 evoked qualitatively identical and quantitatively similar cellular phenotypes in our experimental system. Like a number of other related protein pairs, EVI1 and MDS1/EVI1 differ from each other by the absence or presence of an N-terminal PR domain, respectively. In many such protein pairs, the variant lacking the PR domain has oncogenic and the PR-containing variant tumor suppressive properties [45]. Likewise, Evi1 and Mds1/Evi1 exhibited opposing biological activities in some previous experiments [181920, 37]. However, in other assay systems, Evi1 elicited specific effects, whereas Mds1/Evi1 was inactive [192021], and in yet others, the expression of the two protein variants had the same biological consequences [21, 37, 46, 47]. Thus, it appears that EVI1 and MDS1/EVI1 may act in a similar, different, or opposite manner depending on the biological effect and the experimental system investigated. Notably, however, two recent studies reported that overexpression of EVI1 and MDS1/EVI1 had contrary effects on prognosis in ovarian cancer [37] and in AML [11]. Comparable data for MDS are not available at the present time. Although our results show that both EVI1 and MDS1/EVI1 bring about phenotypes that may be relevant for peripheral blood cytopenia in MDS, their effects on immature MDS cells and/or the prognostic significance of their overexpression in MDS may differ.
###end p 43
###begin p 44
###xml 95 99 95 99 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 343 348 343 348 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N-RAS</italic>
###xml 355 357 355 357 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B48" ref-type="bibr">48</xref>
###xml 357 359 357 359 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B49" ref-type="bibr">49</xref>
###xml 359 361 359 361 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B50" ref-type="bibr">50</xref>
###xml 361 363 361 363 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B51" ref-type="bibr">51</xref>
###xml 363 365 363 365 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B52" ref-type="bibr">52</xref>
###xml 655 659 655 659 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 759 763 759 763 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 826 830 826 830 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 922 923 922 923 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 925 927 925 927 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B53" ref-type="bibr">53</xref>
###xml 927 929 927 929 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B54" ref-type="bibr">54</xref>
###xml 929 931 929 931 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B55" ref-type="bibr">55</xref>
###xml 967 971 967 971 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1328 1332 1328 1332 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
###xml 1383 1387 1383 1387 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1</italic>
In summary, our study confirms and extends previous results, demonstrating that the effects of EVI1 on the proliferation, differentiation, and death of hematopoietic cells strongly depend on cell lineage and the stage of maturation. Such seemingly contradictory phenotypes have also been observed after experimental expression of an activated N-RAS gene [4849505152] and probably reflect the multifaceted roles of these genes in the complex pathologies of MDS and AML. In the present study, we established a cell-culture model that recapitulates cellular phenotypes which may be relevant to the pathology of MDS in response to the inducible expression of EVI1. Based on our own data and those of others, we propose the following working model for the role of EVI1 in normal and malignant hematopoiesis: In the former context, EVI1 promotes the proliferation of immature cells and is down-regulated during differentiation [7, 535455]. In MDS, pathologically activated EVI1 expression augments proliferation and/or survival of immature malignant cells, but the inability to down-regulate this gene properly causes differentiation failure and consequent peripheral pancytopenia. In AML, additional genetic and/or epigenetic alterations keep cells in a state sufficiently immature to benefit from the growth-promoting properties of EVI1, and/or they overcome the failure of more mature, EVI1-expressing cells to differentiate.
###end p 44
###begin p 45
###xml 194 202 <span type="species:ncbi:9606">Children</span>
###xml 951 955 <span type="species:ncbi:9925">goat</span>
###xml 961 966 <span type="species:ncbi:10090">mouse</span>
This work was supported by grants P17896-B14, P19795-B12, and P20920-B12 (all to R. W.) from the Austrian Science Foundation (FWF). We gratefully acknowledge Dr. Gerard Grosveld of the St. Jude Children's Research Hospital (Memphis, TN, USA) for providing U937T cells and the pUHD10S vector, Dr. Hiroyuki Hamaguchi, Musashino Red Cross Hospital (Tokyo, Japan), for his gift of HNT-34 cells, and Dr. Michael Baumann, Wright State University (Dayton, OH, USA), for supplying MPD cells. We thank Dr. Andreas Spittler, Dr. Herbert Strobl, and Dr. Peter Valent of the Medical University of Vienna (Austria) and Dr. Regina Grillari of the University of Natural Resources and Applied Life Sciences (Vienna, Austria) for discussion and valuable advice. Dr. Nina Brandl at the Medical University of Vienna helped with immunofluorescence microscopy, and Dr. Lukas Mach at the University of Natural Resources and Applied Life Sciences provided an aliquot of the goat anti-mouse antibody. Apoptosis experiments were analyzed at the Cell Sorting Core Facility of the Medical University of Vienna.
###end p 45
###begin article-title 46
Myelodysplastic syndromes: the complexity of stem-cell diseases
###end article-title 46
###begin article-title 47
Myelodysplastic syndromes
###end article-title 47
###begin article-title 48
The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia
###end article-title 48
###begin article-title 49
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia
###end article-title 49
###begin article-title 50
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
###end article-title 50
###begin article-title 51
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements
###end article-title 51
###begin article-title 52
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia
###end article-title 52
###begin article-title 53
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations
###end article-title 53
###begin article-title 54
Expression of the Evi-1 gene in myelodysplastic syndromes
###end article-title 54
###begin article-title 55
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration
###end article-title 55
###begin article-title 56
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
###end article-title 56
###begin article-title 57
Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene
###end article-title 57
###begin article-title 58
Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression
###end article-title 58
###begin article-title 59
Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends
###end article-title 59
###begin article-title 60
Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family
###end article-title 60
###begin article-title 61
###xml 96 102 <span type="species:ncbi:10090">murine</span>
Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation
###end article-title 61
###begin article-title 62
Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs
###end article-title 62
###begin article-title 63
The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator
###end article-title 63
###begin article-title 64
Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements
###end article-title 64
###begin article-title 65
MDS1/EVI1 enhances TGF-beta 1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta 1
###end article-title 65
###begin article-title 66
###xml 154 158 <span type="species:ncbi:10090">mice</span>
Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice
###end article-title 66
###begin article-title 67
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">Children</span>
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties
###end article-title 67
###begin article-title 68
###xml 41 45 <span type="species:ncbi:10090">mice</span>
EVI1 induces myelodysplastic syndrome in mice
###end article-title 68
###begin article-title 69
EVI1 abrogates interferon-alpha response by selectively blocking PML induction
###end article-title 69
###begin article-title 70
Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis
###end article-title 70
###begin article-title 71
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
###end article-title 71
###begin article-title 72
Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements
###end article-title 72
###begin article-title 73
Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis
###end article-title 73
###begin article-title 74
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 189 196 <span type="species:ncbi:9606">patient</span>
Establishment of a novel human myeloid leukemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, p210 and p190 BCR/ABL chimeric transcripts from a patient with AML after MDS with 3q21q26 syndrome
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cell line that differentiates to all myeloid lineages and expresses neutrophil secondary granule genes
###end article-title 75
###begin article-title 76
The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death
###end article-title 76
###begin article-title 77
EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity
###end article-title 77
###begin article-title 78
Interaction of EVI1 with CBP and P/CAF results in reversible acetylation of EVI1 and in colocalization in nuclear speckles
###end article-title 78
###begin article-title 79
Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells
###end article-title 79
###begin article-title 80
Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT
###end article-title 80
###begin article-title 81
###xml 109 115 <span type="species:ncbi:10090">murine</span>
Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells
###end article-title 81
###begin article-title 82
###xml 98 105 <span type="species:ncbi:9606">patient</span>
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer
###end article-title 82
###begin article-title 83
Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene
###end article-title 83
###begin article-title 84
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice
###end article-title 84
###begin article-title 85
Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor
###end article-title 85
###begin article-title 86
p21 is a transcriptional target of HOXA10 in differentiating myelomonocytic cells
###end article-title 86
###begin article-title 87
Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
###end article-title 87
###begin article-title 88
Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells
###end article-title 88
###begin article-title 89
Hox genes in hematopoiesis and leukemogenesis
###end article-title 89
###begin article-title 90
The yin-yang of PR-domain family genes in tumorigenesis
###end article-title 90
###begin article-title 91
The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase
###end article-title 91
###begin article-title 92
Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP
###end article-title 92
###begin article-title 93
###xml 53 58 <span type="species:ncbi:9606">human</span>
Mutant 1N-RAS induces erythroid lineage dysplasia in human CD34+ cells
###end article-title 93
###begin article-title 94
H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism
###end article-title 94
###begin article-title 95
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse
###end article-title 95
###begin article-title 96
N-ras-induced growth suppression of myeloid cells is mediated by IRF-1
###end article-title 96
###begin article-title 97
###xml 42 47 <span type="species:ncbi:9606">human</span>
N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation
###end article-title 97
###begin article-title 98
EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML)
###end article-title 98
###begin article-title 99
EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation
###end article-title 99
###begin article-title 100
###xml 22 27 <span type="species:ncbi:9606">human</span>
In vitro expansion of human cord blood CD36(+) erythroid progenitors: temporal changes in gene and protein expression
###end article-title 100
###begin p 101
###xml 184 189 184 189 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 190 201 190 201 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">homeobox A9</italic>
###xml 233 236 233 236 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 237 279 237 279 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">myeloid/lymphoid or mixed lineage leukemia</italic>
###xml 281 286 281 286 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N-RAS</italic>
###xml 287 304 287 304 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">neuroblastoma RAS</italic>
Abbreviations: 7-AAD=7-amino-actinomycin D, AML=acute myeloid leukemia, DAPI=4',6'-diamidino-2-phenylindole dihydrochloride, EVI1=ecotropic viral integration site 1, HA=hemagglutinin, HOXA9=homeobox A9, MDS=myelodysplastic syndrome, MLL=myeloid/lymphoid or mixed lineage leukemia, N-RAS=neuroblastoma RAS, PR=PRDI-BF1/Blimp-1 and RIZ1 related, sAML=secondary AML, TPA=12-O-tetradecanoylphorbol 13-acetate
###end p 101
###begin p 102
###xml 0 56 0 56 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Expression of EVI1 and MDS1/EVI1 in U937T transfectants.</bold>
###xml 1198 1203 <span type="species:ncbi:9606">human</span>
###xml 1314 1319 <span type="species:ncbi:9606">human</span>
Expression of EVI1 and MDS1/EVI1 in U937T transfectants. (A) Immunoblot analysis of U937T_EVI1-HA E10 and E14, U937T_MDS1/EVI1-HA M2 and M27, and U937T cells grown in media with or without tetracycline (tet) for 48 h. Experimentally expressed proteins were detected using an antibody recognizing the HA epitope tag (upper panels); hybridization with an antibody against beta-tubulin was used as loading control (lower panels). M/E, MDS1/EVI1. (B) Time-course analysis. Proteins were extracted from exponentially growing E14 or M2 cells maintained in media with or without tetracycline for the indicated times and subjected to immunoblot analysis as described above. (C) Immunofluorescence analysis demonstrating nuclear location of experimentally expressed EVI1 and MDS1/EVI1 proteins. E14, M2, and U937T cells were maintained in the presence or absence of tetracycline for 48 h, fixed, permeabilized, and probed with the HA antibody and a FITC-conjugated secondary antibody. DNA was counterstained with DAPI. Similar results were obtained for clones E10 and M27. (D) Protein extracts prepared from E10, E14, M2, M27, and U937T cells maintained in the absence of tetracycline for 48 h and from the human myeloid leukemia cell lines HNT-34 and MPD were subjected to immunoblot analysis with an antibody recognizing human EVI1 or with a beta-tubulin antibody as a loading control. Small size differences between endogenously and exogenously expressed proteins are a result of the presence of the HA epitope tag in the latter. All experiments were repeated several times and yielded comparable results.
###end p 102
###begin p 103
###xml 0 56 0 56 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1 and MDS1/EVI1 inhibit proliferation of U937T cells.</bold>
EVI1 and MDS1/EVI1 inhibit proliferation of U937T cells. (A) U937T_EVI1-HA E10 (squares), U937T_MDS1/EVI1-HA M2 (diamonds), and U937T cells (triangles) were transferred to media containing 1000 (closed symbols) or 0 (open symbols) ng/ml tetracycline. Two days later, their density was adjusted to 50 cells/mul (Day 0). On the indicated days, viable cells were identified by Trypan blue exclusion and counted in a hematocytometer. Comparable results were obtained for E14 and M27 cells. (B) Immunoblot analysis of E14 cells maintained in media containing the indicated concentrations of tetracycline for 3 days. (Upper panel) Staining with an HA antibody; (lower panel) staining with a beta-tubulin antibody as a loading control. (C) E14 and U937T cells were transferred to media containing 1000 (circles), 5 (asterisks), 3 (crosses), 2 (triangles), 0.5 (squares), or 0 (diamonds) ng/ml tetracycline and adjusted to the same starting density. On the indicated days thereafter, viable cells were identified by Trypan blue exclusion and counted in a hematocytometer. All experiments were repeated several times and yielded comparable results.
###end p 103
###begin p 104
###xml 26 27 26 27 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 29 30 29 30 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 53 0 53 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">EVI1 and MDS1/EVI1 cause G<sub>0</sub>/G<sub>1</sub> arrest in U937T cells.</bold>
###xml 497 498 497 498 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 523 524 523 524 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 546 547 546 547 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1071 1072 1071 1072 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1085 1086 1085 1086 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1100 1101 1100 1101 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
EVI1 and MDS1/EVI1 cause G0/G1 arrest in U937T cells. (A) U937T_EVI1-HA E14, U937T_MDS1/EVI1-HA M2, and U937T cells were maintained in the presence or absence of tetracycline for 4 days. Nuclear DNA content was analyzed by flow cytometry after staining with propidium iodide. Similar data were obtained with E10 and M27 cells. (B) Quantitative evaluation of cell-cycle experiments. The percentage of cells in each phase of the cell cycle is indicated. E, M, U, Results obtained for U937T_EVI1-HA (n=5), U937T_MDS1/EVI1-HA (n=4), and U937T cells (n=3), respectively. Data have been derived from several independent experiments. Values for U937T_EVI1-HA clones E10 and E14 were pooled, as were values for U937T_MDS1/EVI1-HA clones M2 and M27. Open and solid bars, Cells grown in the presence or absence of tetracycline, respectively. Asterisks above bars indicate the level of significance between cells grown in the presence or absence of tetracycline. Asterisks above brackets indicate the level of significance as compared with U937T cells under the same conditions. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 104
###begin p 105
###xml 0 90 0 90 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Induction of EVI1 or MDS1/EVI1 in U937T cells increases the rate of spontaneous apoptosis.</bold>
###xml 519 520 519 520 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 545 546 545 546 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 568 569 568 569 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1002 1003 1002 1003 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1016 1017 1016 1017 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1031 1032 1031 1032 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Induction of EVI1 or MDS1/EVI1 in U937T cells increases the rate of spontaneous apoptosis. U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and U937T cells were maintained in the presence (open bars) or absence (solid bars) of tetracycline for 5 days, stained with Annexin V-FITC and 7-AAD, and analyzed by flow cytometry. The percentages of viable (double-negative), early-apoptotic (Annexin V-positive 7-AAD-negative), and late-apoptotic/necrotic (double-positive) cells are indicated. E, M, U: results obtained for U937T_EVI1-HA (n=6), U937T_MDS1/EVI1-HA (n=4), and U937T cells (n=4), respectively. Data have been derived from several independent experiments. Values for U937T_EVI1-HA clones E10 and E14 were pooled, as were values for U937T_MDS1/EVI1-HA clones M2 and M27. Asterisks above bars indicate the level of significance between cells grown in the presence or absence of tetracycline. Asterisks above brackets indicate the level of significance as compared with U937T cells under the same conditions. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 105
###begin p 106
###xml 0 110 0 110 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Expression of EVI1 or MDS1/EVI1 causes massive apoptosis in U937T cells exposed to a differentiation stimulus.</bold>
###xml 863 864 863 864 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 889 890 889 890 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 912 913 912 913 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1533 1534 1533 1534 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1547 1548 1547 1548 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1562 1563 1562 1563 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1573 1574 1573 1574 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
Expression of EVI1 or MDS1/EVI1 causes massive apoptosis in U937T cells exposed to a differentiation stimulus. U937T_EVI1-HA, U937T_MDS1/EVI1-HA, and parental U937T cells were transferred to media with or without tetracycline. On the next day (Day 1 of the experiment), 50 ng/ml TPA was added to one-half of each culture. On Days 4 (upper panel) and 6 (lower panel), one aliquot of each culture was stained with a PE-conjugated CD11b antibody and another aliquot with Annexin V-FITC and 7-AAD, and cells were analyzed by flow cytometry. The percentages of CD11b-positive cells as well as the percentages of viable (Annexin V-negative 7-AAD-negative), early-apoptotic (Annexin V-positive 7-AAD-negative), and late-apoptotic/necrotic (Annexin V-positive 7-AAD-positive) cells are shown in separate panels as indicated. E, M, U: results obtained with U937T_EVI1-HA (n=4), U937T_MDS1/EVI1-HA (n=4), and U937T cells (n=4), respectively. Data have been derived from several independent experiments. Values for U937T_EVI1-HA clones E10 and E14 were pooled, as were values for U937T_MDS1/EVI1-HA clones M2 and M27. Open bars, Cells maintained in the presence of tetracycline and the absence of TPA; hatched bars, cells maintained in the presence of tetracycline and TPA; shaded bars, cells maintained in the absence of tetracycline and TPA; solid bars, cells maintained in the absence of tetracycline and the presence of TPA. Asterisks above bars indicate the level of significance as compared with U937T cells under the same conditions. *, P < 0.05; **, P < 0.01; ***, P < 0.001. #, On Day 6 of the experiment, U937T_MDS1/EVI1-HA cells without tetracycline had lost viability to an extent that did not allow a reliable distinction between early- and late-apoptotic cells. Therefore, only the number of viable cells is indicated.
###end p 106
###begin p 107
###xml 0 122 0 122 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TUNEL assays confirm massive apoptosis in EVI1- or MDS1/EVI1-expressing U937T cells exposed to a differentiation stimulus.</bold>
###xml 713 714 713 714 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 739 740 739 740 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 762 763 762 763 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1383 1384 1383 1384 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1397 1398 1397 1398 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1412 1413 1412 1413 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
TUNEL assays confirm massive apoptosis in EVI1- or MDS1/EVI1-expressing U937T cells exposed to a differentiation stimulus. (A) U937T_EVI1-HA E14, U937T_MDS1/EVI1-HA M27, and parental U937T cells were transferred to media with or without tetracycline. On the next day (Day 1 of the experiment), 50 ng/ml TPA was added to one-half of each culture. On Day 5, DNA breaks were labeled using terminal deoxynucleotidyl transferase and FITC-labeled dUTP and quantified by flow cytometry. Similar results were obtained with E10 and M2 cells. (B) Quantitative evaluation of TUNEL experiments. The percentage of TUNEL-positive (dead) cells is indicated for each culture condition. E, M, U: data obtained with U937T_EVI1-HA (n=3), U937T_MDS1/EVI1-HA (n=4), and U937T cells (n=3), respectively. Data have been derived from several independent experiments. Values for U937T_EVI1-HA clones E10 and E14 were pooled, as were values for U937T_MDS1/EVI1-HA clones M2 and M27. Open bars, Cells maintained in the presence of tetracycline and the absence of TPA; hatched bars, cells maintained in the presence of tetracycline and TPA; shaded bars, cells maintained in the absence of tetracycline and TPA; solid bars, cells maintained in the absence of tetracycline and the presence of TPA. Asterisks above bars indicate the level of significance as compared with U937T cells under the same conditions. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 107

